The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why the issue is hotly debated.
Subscribe to our e-newsletterVIEW OUR CURRENT ISSUE >
Tagsbiotechnology Biotechnology Industry BIOTECH Benefits of biotech crops healthcare patent Sustainability BIO Events climate change Health Care BIO International Convention agriculture biotech industry FDA Plant biotechnology BIO EVENT Food health GMOs Intellectual Property
- Most Popular
Latest VideoBIO Buzz Center with Nelson Griggs , Executive Vice President of Global Listing Services of NASDAQ View All >